

TO:	Dare County Healthcare Providers	FROM:	Department of Health & Human Services
PAGES: INCLUDES COVER	11	PHONE:	252.475.5003
SUBJECT:	Coronavirus Guidance & Documents	DATE:	March 10, 2020

# Dear Colleagues,

Attached you will find updated COVID-19 guidance, PUI form, and home care isolation guidance. Please be advised, this guidance replaces all previous versions.

We are providing an additional webinar Wednesday March 11, 2020 at 8:00 am, where we will review this updated guidance with you. If you have already participated in a webinar, you are welcome to participate again, as this guidance has been updated.

### **Webinar Details**

To join the meeting on a computer or mobile phone: https://bluejeans.com/655377850?src=calendarLink

Phone Dial-in

+1.408.740.7256 (US (San Jose))

+1.408.317.9253 (US (Primary))

Global Numbers: https://www.bluejeans.com/premium-numbers

Meeting ID: 655 377 850

Want to test your video connection? <a href="https://bluejeans.com/111">https://bluejeans.com/111</a>

Below are essential numbers that you may find helpful for COVID-19:

DCDHHS Clinical Services: 252.475.5003

DCDHHS Fax: 252.473.2153

State EPI On Call Number: 919.733.3419

COVID-19 General Information Line: 866.462.3821

DCDHHS After Hours Phone: 252.216.8703

#### Thanks

Notice of Confidentiality: The documents accompanying this transmission may contain confidential health information that is legally privileged. This information is intended for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation and is required to destroy the information after its stated need has been fulfilled. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and destroy these documents





ROY COOPER • Governor

MANDY COHEN, MD, MPH • Secretary

ELIZABETH CUERVO TILSON, MD, MPH • State Health Director

MARK T. BENTON • Assistant Secretary for Public Health

Division of Public Health

March 10, 2020 (replaces version dated March 8, 2020)

To: All North Carolina Clinicians and Laboratories From: Zack Moore, MD, MPH, State Epidemiologist

Scott Shone, PhD, HCLD (ABB), Public Health Laboratory Director

Re: Coronavirus Disease 2019 (5 pages)

This memo is intended to provide the latest information to all North Carolina clinicians and laboratory staff regarding the Coronavirus Disease 2019 (COVID-19). This version includes the following updates:

- Updated criteria to guide evaluation for patients under investigation for COVID-19,
- Updated guidance for discontinuation of isolation for Persons Under Investigation.
- Updated specimen collection instructions, specifically to include NP and OP swabs in a single tube, and
- Storage of any unused portions of NCSLPH COVID-19 specimen collection kits for future use.

### **Summary**

A respiratory disease named "coronavirus disease 2019" (abbreviated "COVID-19") caused by a novel coronavirus named "SARS-CoV-2" was first detected in China in late 2019 and has subsequently spread to many other countries, including the United States. The World Health Organization announced a Public Health Emergency of International Concern on January 30 and the U.S. Department of Health and Human Services declared a public health emergency on January 31, 2020.

This is a rapidly evolving situation. The most up to date information and guidance can be found at <a href="https://www.cdc.gov/coronavirus/2019-ncov/index.html">https://www.cdc.gov/coronavirus/2019-ncov/index.html</a> and <a href="https://epi.dph.ncdhhs.gov/cd/coronavirus/providers.html">https://epi.dph.ncdhhs.gov/cd/coronavirus/providers.html</a>.

# Case Investigation and Testing

Clinicians should use their judgment to determine if a patient has signs and symptoms compatible with COVID-19 and whether the patient should be tested. Decisions on which patients receive testing should be based on the local epidemiology of COVID-19, as well as the clinical course of illness. Most patients with confirmed COVID-19 have developed fever<sup>1</sup> and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing). Clinicians are strongly encouraged to also consider and test for other causes of respiratory illness, including infections such as influenza.

Testing at the North Carolina State Laboratory of Public Health (NCSLPH) is available with prior approval by the local health department for the county of the health care facility, or the state epidemiologist on call. Patients meeting the following criteria for a Person Under Investigation (PUI) will be considered for testing at NCSLPH:

- 1) Fever<sup>1</sup> OR signs/symptoms of lower respiratory illness (e.g., cough, shortness of breath) in any person, including healthcare workers<sup>2</sup>, who has had close contact<sup>3</sup> with a laboratory-confirmed<sup>4</sup> COVID-19 patient within 14 days of symptom onset.
- 2) Fever<sup>1</sup> AND signs/symptoms of lower respiratory illness (e.g., cough, shortness of breath) AND negative influenza test (rapid or PCR) and no other more likely diagnosis.

Commercial laboratory testing to detect COVID-19 is now available. Testing should not be done for asymptomatic persons. Prior authorization for testing is **not** required for commercial lab testing **but** patients being tested will be considered PUIs and *must be isolated* either at home or in a hospital based on their need for care. Providers should 1) give the home isolation document to all patients being tested that do not require hospitalization, and 2) complete and submit the PUI form to the patient's local health department at the time the test is ordered. These documents can also be found here under "Patients Under Investigation."

### Reporting

- Effective February 3, 2020, physicians and laboratories in North Carolina are required to immediately report when novel coronavirus infection is reasonably suspected to exist.
- Any cluster of severe acute respiratory illness in healthcare workers in the United States should prompt immediate notification of local or state public health for further investigation and testing.

### **Control Measures**

- Patients undergoing testing will be considered PUI. Providers should give the Guidance for Persons Under Investigation to all patients undergoing testing.
- Isolation can be discontinued if the test is negative. If the test is positive, the patient should remain isolated until cleared by local public health officials.

### Infection Control

- CDC currently recommends a cautious approach to management of known or suspected cases.
  - Standard, contact, and airborne precautions are recommended for management of patients in healthcare settings with known or suspected COVID-19. These include:
    - Use of fit-tested NIOSH-approved N95 or higher-level respirators
    - Use of gowns, gloves and eye protection (e.g., goggles or face shield)
    - Use of negative-pressure airborne infection isolation rooms if available
  - Patients should be asked to wear a surgical mask as soon as they are identified as having symptoms of respiratory illness
  - o Isolate patients in a private room with the door closed (use an airborne isolation room, if possible).
  - Patients with known or suspected COVID-19 should continue to wear a mask if placed in a private, non-airborne isolation room or if they must be moved from their room.
- As the situation continues to evolve, please find updated guidance at <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html</a>.

### Treatment

- No vaccine or specific treatment for COVID-19 is available; care is supportive.
- Corticosteroids should be avoided unless indicated for other reasons (for example, chronic obstructive pulmonary disease exacerbation or septic shock).

# **Testing**

- NCSLPH is currently conducting testing to detect COVID-19 using the CDC 2019-nCoV real-time RT-PCR Diagnostic Panel which has been granted Emergency Use Authorization (EUA) from the FDA.
  - o FDA EUA Fact Sheet for Healthcare Providers
  - FDA EUA Fact Sheet for Patients
- If using an SLPH collection kit and mailing specimens on a Friday for an overnight Saturday delivery, you must email <a href="style="style-type: square;">slph.covid19@dhhs.nc.gov</a> to request a Saturday delivery return service label, which will then be emailed to you. The NCSLPH requires approval from either the Local Health Department where the provider is located or the State Communicable Disease Branch prior to testing for COVID-19. Health care providers in consultation with the state Communicable Disease Branch (919-733-3419, available 24/7) or their <a href="local health department">local health department</a> will conduct a risk assessment to determine if individuals meet the NC criteria for diagnostic testing at the SLPH. When the criteria are met, a NC Patient Under Investigation (PUI) case file is created in REDCap and a REDCap ID is subsequently generated documenting approval for testing. The REDCap ID will be referenced on the laboratory testing report form under 'NC PUI Number'.
- Commercial laboratory testing is now available and should be limited only to symptomatic persons. Prior authorization is not required for commercial laboratory testing but individuals will be considered a PUI.
- Persons in whom COVID-19 infection is suspected should also be evaluated for common causes of community-acquired respiratory illness, if not already done. In persons who are close contacts of known cases, state and local public health should be consulted even if the patient tests positive for a respiratory pathogen other than flu. Note: For biosafety reasons, viral culture should not be attempted in cases meeting the PUI criteria.
- Point-of-Care tests which are not FDA approved should not be used.

## **Specimen Collection**

- Specimens should be collected as soon as possible once a PUI is identified, regardless of the time of symptom onset.
- Health care providers or public health personnel collecting specimens should wear recommended PPE as
  described in <u>What Healthcare Personnel Should Know about Caring for Patients with Confirmed or Possible</u>
  <u>COVID-19 Infection</u>
- For initial diagnostic testing to detect COVID-19, NC recommends collecting and testing upper respiratory (nasopharyngeal AND oropharyngeal swabs), and lower respiratory (sputum, if possible) for those patients with productive coughs. Induction of sputum is not recommended.
  - Nasopharyngeal <u>AND</u> oropharyngeal swabs (NP/OP swabs) should be collected separately and both swabs should be placed into one vial of transport medium.
    - Use only synthetic fiber swabs with plastic or metal shafts. Do not use calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing. Place both NP and OP swabs immediately into a single sterile tube containing 2-3 ml of viral transport medium.
    - To collect the nasopharyngeal specimen, place the swab into the nostril parallel to the palate until resistance is encountered. Leave the swab in place for a few seconds to absorb secretions. Slowly remove swab while rotating it. Place the tip into the vial of sterile transport medium. Aseptically cut off the applicator stick so that it does not protrude above the rim of the tube and cap. Cap the vial.
    - To collect the oropharyngeal specimen (e.g., throat swab) use a fresh swab to swab the posterior pharynx and tonsillar areas, avoiding the tongue, teeth, and gums. Uncap the vial of transport medium with the NP swab and place the fiber end of OP swab into the same vial. Aseptically cut off the applicator stick so that it does not protrude above the rim of the tube and cap vial. LABEL THE VIAL: NP/OP and include the patient's name, date of birth, REDCap#, and date/time of collection.
  - Sputum, if possible when a productive cough is present. Sputum should not be induced.

- Have the patient rinse the mouth with water and then expectorate deep cough sputum directly into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container such as a 50 ml conical tube. LABEL THE TUBE: Sputum and include the patient's name, date of birth, REDCap#, and date/time of collection.
- Store specimens at 2-8°C for up to 72 hours following collection. If longer storage is required, store at -70°C.
- Additional guidance on collection, handling, and testing of clinical specimens is provided at the following locations:
  - o <a href="https://slph.ncpublichealth.com/bioterrorism/2019-ncov.asp">https://slph.ncpublichealth.com/bioterrorism/2019-ncov.asp</a>
  - o https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html

Note: For local health departments that have previously ordered and received NCSLPH COVID-19 Specimen Collection Kits, unused collection materials can be kept for future use. Unused vials of viral transport medium should be stored at 2-8°C.

### Specimen Packaging and Shipment

- Specimens should be packaged and shipped as UN3373 Category B.
  - <u>Sentinel Level Clinical Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases, Packing and Shipping Infectious Substances</u>
- All approved specimens should be directly shipped to the NCSLPH via overnight commercial courier.
  - Ship refrigerated specimens to NCSLPH on frozen cold packs
  - o If a specimen is frozen at -70°C, ship on dry ice.
  - o Specimens should be shipped Monday Friday using a commercial overnight courier
  - Shipping address:

Attention: Virology/Serology Unit COVID-19

North Carolina State Laboratory of Public Health 4312 District Drive Raleigh, NC 27607-5490

- o If using an SLPH collection kit and mailing specimens on a Friday for an overnight Saturday delivery, you must email <a href="slph.covid19@dhhs.nc.gov">slph.covid19@dhhs.nc.gov</a> to request a Saturday delivery return service label, which will then be emailed to you.
- Send overnight courier package tracking number to slph.covid19@dhhs.nc.gov
- All specimen submissions must have a fully completed <u>NCSLPH Virology/Serology Form.</u>

# Specimen Rejection Criteria

- Samples without a REDCap ID or Local Health Department/Communicable Disease Branch approval for testing.
- Specimens not kept at 2-8°C (≤72 hrs) or if specimens have not been frozen at -70°C and they are >72 hrs old.
- Incomplete specimen labeling or documentation.
- Inappropriate specimen type.
- Insufficient specimen volume for testing.

# **Result Reporting**

- Turnaround time for testing will be dependent on testing volumes.
- Specimens testing positive at the NCSLPH will be reported as "Presumptive positive 2019-nCoV"
  - o The specimen will be immediately shipped to the CDC for confirmatory testing.
  - o Presumptive positive results are public health actionable.
  - Confirmatory results are expected 24-72 hours following receipt at CDC, depending on testing volume.
- Specimens testing negative at the NCSLPH will be reported as 2019-nCoV "Not Detected."

#### Clinical Laboratory Safety Guidance

- Laboratorians should use appropriate precautions when handling specimens that may contain SARS-CoV-2. Timely communication between clinical and laboratory staff is essential to minimize the risk associated when handling specimens from patients with possible COVID-19. Such specimens should be labeled accordingly, and the laboratory should be alerted to ensure proper specimen handling.
  - Additional information can be found in:
    - The CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens
      Associated with Coronavirus Disease 2019 (COVID-19)

# **Additional Information for Clinical Laboratory Testing**

- Specimens initially tested in a clinical diagnostic laboratory regulated by CLIA using a laboratory developed test (LDT) must abide by <u>FDA regulations</u> that require registration of the assay employed.
  - Policy for Diagnostic Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to EUA for Coronavirus Disease-2019 during the Public Health
- Immediate notification of the detection of COVID-19 to the Communicable Disease Branch (919-733-3419, available 24/7) is required.

## Requests for Additional Information From NCSLPH

- For general information, non-urgent LABORATORY questions about specimen collection, testing, and reporting please email the NCSLPH COVID-19 helpdesk at <a href="mailto:slph.covid19@dhhs.nc.gov">slph.covid19@dhhs.nc.gov</a>.
- For critical laboratory-related questions during normal business hours (8am 5pm, Monday Friday) please call the SLPH Customer Service line at 919-733-3937.
- For critical laboratory-related questions after business hours and on weekends, please contact the Bioterrorism and Emerging Pathogens Duty Phone at 919-807-8600.

### Notes:

<sup>1</sup>Fever may be subjective or confirmed. Fever may not be present in some patients, such as those who are very young, elderly, immunosuppressed, or taking certain fever-lowering medications. Clinical judgment should be used to guide testing of patients in such situations.

<sup>2</sup>For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19 without laboratory confirmation

<sup>3</sup>Close contact is defined as:

- a) being within approximately 6 feet (2 meters), of a COVID-19 case for a prolonged period of time while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection); close contact can include caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case.

   or —
- b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on) while not wearing recommended personal protective equipment.

<sup>4</sup>Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for COVID-19 patients in other countries.

CDC	2019-nCoV ID:	Form App	proved: OMB: 0920-1011 Exp. 4/23/2020				
PATIENT IDENTIFIER INFORMATION IS NOT TRANSMITTED TO CDC							
Patient first name	Patient last name	tient last name Date of birth (MM/DD/YYYY):/					
PATIENT IDENT	IFIER INFORMATION	I IS NOT TRANSMITTED TO CDC					
Human Inf		2019 Novel Coronaviru (PUI) and Case Repo					
Reporting jurisdiction:  Reporting health department:  Contact ID a:  a. Only complete if case-patient is a known contact of prior sour CA102034567 -01 and CA102034567 -02. Pror NNDSS reported.	CDC NND		Confirmed case CA102034567 has contacts				
Interviewer information Name of interviewer: Last	First						
Affiliation/Organization:							
Basic information							
What is the current status of this person?  Patient under investigation (PUI)  Laboratory-confirmed case  Report date of PUI to CDC (MM/DD/YYYY):  Report date of case to CDC (MM/DD/YYYY):  County of residence: State of residence:  Race (check all that apply):  Asian  Black  Native Hawaiia  White  Other, specify: Date of birth (MM/DD/YYYY):  Age: Age units(yr/mo/day):  Symptoms present  If symptomatic, onset	n/Other Pacific Islander	Date of first positive specimen collection (MM/DD/YYYY):	Was the patient hospitalized?  Yes No Unknown  If yes, admission date 1				
during course of illness: date (MM/DD/YYYY):  Symptomatic Asymptomatic Unknown  Unknown	Still symptomatic Symptoms resolved,	☐ Unknown symptom status , unknown date	Date of death (MM/DD/YYYY):/ Unknown date of death				
Travel to Hubei lab Travel to mainland China And Travel to other non-US country lab specify:	e facility (as a patient, worker any of the following exportment of the following exportment of the following exportment of the following exportment of the following exposure of the facility of the following exposure of the facility of th	ker or visitor) in China?  Yes  No  soures (check all that apply):  ther  Exposure to a cluster of pe-patient respiratory distress of unkranother  Other, specify:  P-patient Unknown HCW  Se? Yes, nCoV ID of source case:					

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011).



Other, Specify:

Additional State/local Specimen IDs:

CDC 2040 . C-1/1D	
CDC 2019-nCoV ID:	

Form Approved: OMB: 0920-1011 Exp. 4/23/2020

# Human Infection with 2019 Novel Coronavirus Person Under Investigation (PUI) and Case Report Form

Symptoms, clinical course, past medical history and social history Collected from (check all that apply): Patient interview Medical record review During this illness, did the patient experience any of the following symptoms? **Symptom Present?** Fever >100.4F (38C)c □Yes □No  $\Box$ Unk Unk Subjective fever (felt feverish) Yes No Chills Yes Νo Unk Muscle aches (myalgia) Yes Πo  $\Box$ Unk Runny nose (rhinorrhea) No Yes Unk Unk Sore throat Yes No Cough (new onset or worsening of chronic cough) □Yes No Unk Shortness of breath (dyspnea) Yes ΠNο Unk Yes No Unk Nausea or vomiting Yes No Unk Headache Yes No Unk Abdominal pain Diarrhea (≥3 loose/looser than normal stools/24hr period) ☐Yes ☐No ∏Unk Other, specify: Pre-existing medical conditions? Yes No Unknown Chronic Lung Disease (asthma/emphysema/COPD) Yes No Unknown Yes Пио Unknown Diabetes Mellitus Cardiovascular disease Yes □No Unknown Chronic Renal disease Yes ∏No Unknown Yes ПNо Unknown Chronic Liver disease □Yes □No Unknown Immunocompromised Condition Neurologic/neurodevelopmental □No Yes Unknown (If YES, specify) Yes No (If YES, specify) Other chronic diseases Unknown If female, currently pregnant Yes Пио Unknown No Yes Unknown Current smoker Yes No Unknown Former smoker Respiratory Diagnostic Testing Specimens for COVID-19 Testing Pos Pend. Not done Specimen Date State Lab Test Neg Specimen Sent to Type ID Collected CDC Tested NP Swab Influenza rapid Ag □ A □ B Influenza PCR □ A □ B **OP Swab** RSV Sputum H. metapneumovirus Other, Parainfluenza (1-4) Specify: Adenovirus Rhinovirus/enterovirus Coronavirus (OC43, 229E, HKU1, NL63) M. pneumoniae C. pneumoniae

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011).



# Division of Public Health Communicable Disease Branch

# Infection Prevention Recommendations for Individuals Confirmed to have, or Being Evaluated for, 2019 Novel Coronavirus (COVID-19) Infection Who Receive Care at Home

Individuals who are confirmed to have, or are being evaluated for, COVID-19 should follow the prevention steps below until a healthcare provider or local or state health department says they can return to normal activities.

# Stay home except to get medical care

You should restrict activities outside your home, except for getting medical care. Do not go to work, school, or public areas, and do not use public transportation or taxis.

# Call ahead before visiting your doctor

Before your medical appointment, call the healthcare provider and tell them that you have, or are being evaluated for, COVID-19 infection. This will help the healthcare provider's office take steps to keep other people from getting infected. Ask your healthcare provider to call the local or state health department.

# **Monitor your symptoms**

Seek prompt medical attention if your illness is worsening (e.g., difficulty breathing). **Before** going to your medical appointment, call the healthcare provider and tell them that you have, or are being evaluated for, COVID-19 infection. Ask your healthcare provider to call the local or state health department.

### Wear a facemask

You should wear a facemask that covers your nose and mouth when you are in the same room with other people and when you visit a healthcare provider. People who live with or visit you should also wear a facemask while they are in the same room with you.

# Separate yourself from other people in your home

As much as possible, you should stay in a different room from other people in your home. Also, you should use a separate bathroom, if available.

# Avoid sharing household items

You should not share dishes, drinking glasses, cups, eating utensils, towels, bedding, or other items with other people in your home. After using these items, you should wash them thoroughly with soap and water.

### Cover your coughs and sneezes

Cover your mouth and nose with a tissue when you cough or sneeze, or you can cough or sneeze into your sleeve. Throw used tissues in a lined trash can, and immediately wash your hands with soap and water for at least 20 seconds or use an alcohol-based hand rub.

### Wash your hands

Wash your hands often and thoroughly with soap and water for at least 20 seconds. You can use an alcohol-based hand sanitizer if soap and water are not available and if your hands are not visibly dirty. Avoid touching your eyes, nose, and mouth with unwashed hands.

# Prevention Steps for Caregivers and Household Members of Individuals Confirmed to have, or Being Evaluated for, COVID-19 Infection Being Cared for in the Home

If you live with, or provide care at home for, a person confirmed to have, or being evaluated for, COVID-19 infection please follow these guidelines to prevent infection:

# Follow healthcare provider's instructions

Make sure that you understand and can help the patient follow any healthcare provider instructions for all care.

# Provide for the patient's basic needs

You should help the patient with basic needs in the home and provide support for getting groceries, prescriptions, and other personal needs.

# Monitor the patient's symptoms

If they are getting sicker, call his or her medical provider and tell them that the patient has, or is being evaluated for, COVID-19 infection. This will help the healthcare provider's office take steps to keep other people from getting infected. Ask the healthcare provider to call the local or state health department.

# Limit the number of people who have contact with the patient

ш	If possible, have <b>only one caregiver</b> for the patient.
	Other household members should stay in another home or place of residence. If this is not possible, they should stay
	in another room, or be separated from the patient as much as possible. Use a separate bathroom, if available.
	Restrict visitors who do not have an essential need to be in the home.

# Keep older adults, very young children, and other sick people away from the patient

Keep older adults, very young children, and those who have compromised immune systems or chronic health conditions away from the patient. This includes people with chronic heart, lung, or kidney conditions, diabetes, and cancer.

# **Ensure good ventilation**

Make sure that shared spaces in the home have good air flow, such as from an air conditioner or an opened window, weather permitting.

### Wash your hands often

Wash your hands often and thoroughly with soap and water for at least 20 seconds. You can use an alcohol-		
based hand sanitizer if soap and water are not available and if your hands are not visibly dirty.		
Avoid touching your eyes, nose, and mouth with unwashed hands.		
Use disposable paper towels to dry your hands. If not available, use dedicated cloth towels and replace them when		
they become wet.		

# NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

W	ear a facemask and gloves
	blood, body fluids, and/or secretions or excretions, such as sweat, saliva, sputum, nasal mucus, vomit, urine, or feces. Ensure the mask fits over your nose and mouth tightly, and do not touch it during use.
	Throw out disposable facemasks and gloves after using them. Do not reuse.
	Wash your hands immediately after removing your facemask and gloves.
	If your personal clothing becomes contaminated, carefully remove clothing and launder. <b>Wash your hands</b> after handling contaminated clothing.
	Place all used disposable facemasks, gloves, and other waste in a lined container before disposing them with other household waste.
	Remove gloves and wash your hands immediately after handling these items.
Do	o not share dishes, glasses, or other household items with the patient
	Avoid sharing household items. You should not share dishes, drinking glasses, cups, eating utensils, towels, bedding, or other items with a patient who is confirmed to have, or being evaluated for, COVID-19 infection.
	After the person uses these items, you should wash them thoroughly with soap and water.
W	ash laundry thoroughly
	Immediately remove and wash clothes or bedding that have blood, body fluids, and/or secretions or excretions, such
	as sweat, saliva, sputum, nasal mucus, vomit, urine, or feces, on them.
_	Wear gloves when handling laundry from the patient.
	Read and follow directions on labels of laundry or clothing items and detergent. In general, wash and dry with the warmest temperatures recommended on the label.
CI	ean all areas the individual has used often
	Clean all touchable surfaces, such as counters, tabletops, doorknobs, bathroom fixtures, toilets, phones, keyboards,
	tablets, and bedside tables, every day. Also, clean any surfaces that may have blood, body fluids, and/or secretions or excretions on them.
	Wear gloves when cleaning surfaces the patient has come in contact with.
	Use a <b>diluted bleach solution</b> (e.g., dilute bleach with 1 part bleach and 10 parts water) or a household disinfectant with a label that says <b>EPA-registered for coronaviruses</b> . To make a bleach solution at home, add 1 tablespoon of bleach to 1 quart (4 cups) of water. For a larger supply, add ½ cup of bleach to 1 gallon (16 cups) of water.
	Read labels of cleaning products and follow recommendations provided on product labels. Labels contain instructions for safe and effective use of the cleaning product including precautions you should take when applying the product, such as wearing gloves or eye protection and making sure you have good ventilation during use of the product.
	Remove gloves and wash hands immediately after cleaning.
Mo	onitor yourself for signs and symptoms of illness
	regivers and household members are considered close contacts, should monitor their health, and will be asked to limit
	vement outside of the home to the extent possible. Follow the monitoring steps for close contacts listed on the nptom monitoring form.
	If you have additional questions, contact your local health department or call the epidemiologist on call at 919-733-3419
	(available 24/7).
	This guidance is subject to change. For the most up-to-date guidance from CDC, please refer to their website: <a href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html</a>